19 completed, 3 terminated, 3 unknown, 2 recruiting. 28 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 19, Terminated 3, Unknown 3, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 7 | Completed 4, Recruiting 1, Terminated 1, Unknown 1 |
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma JNJ-79635322, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 | Recruiting | Janssen Research & Development, LLC | 276 | 2024-12-04 | 2026-09-25 |
| The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma TG01 - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Oslo University Hospital | 20 | 2023-05-19 | 2025-08-05 |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Best Practice, Ibrutinib - Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | Jennifer Woyach | 10 | 2020-10-23 | 2023-12-26 |
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM Hiltonol, Citarinostat, Lenalidomide - Smoldering Multiple Myeloma | Phase 1 | Active not recruiting | Massachusetts General Hospital | 19 | 2017-03-07 | 2026-10-07 |
| Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma Atezolizumab (1200mg via IV infusion) - Asymptomatic Myeloma | Phase 1 | Terminated | Yale University | 2 | 2017-02-10 | 2020-03-03 |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Anakinra, Dexamethasone, Laboratory Biomarker Analysis - Indolent Plasma Cell Myeloma, Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 14 | 2016-04-01 | 2020-03-25 |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Sargramostim, BB-MPI-03, Montanide - Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM) | Phase 1 | Unknown | Benovus Bio, Inc. | 4 | 2015-01-01 | 2016-04-19 |
| Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma PVX-410 - Smoldering Multiple Myeloma | Phase 1 | Completed | OncoPep, Inc. | 22 | 2012-11-01 | 2016-09-28 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Siltuximab - Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma | Phase 1 | Completed | Janssen Research & Development, LLC | 30 | 2010-10-01 | 2015-01-19 |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma KW-2478, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 95 | 2010-03-01 | 2024-04-25 |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Melphalan, Bortezomib, Dexamethasone - Plasma Cell Myeloma, Plasmacytosis | Phase 1 / Phase 2 | Terminated | University of Colorado, Denver | 3 | 2009-11-01 | 2015-03-09 |
| Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer therapeutic allogeneic lymphocytes, busulfan, cyclosporine - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Completed | OHSU Knight Cancer Institute | 147 | 2005-06-01 | 2017-09-27 |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma total marrow irradiation, melphalan, peripheral blood stem cell transplantation - Refractory Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 54 | 2004-11-01 | 2025-06-06 |
| Pyroxamide in Treating Patients With Advanced Cancer pyroxamide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2002-04-01 | 2013-06-05 | |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2001-08-01 | 2013-02-07 |
| Beta Alethine in Treating Patients With Myeloma beta alethine - Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition | Phase 1 / Phase 2 | Unknown | LifeTime Pharmaceuticals | 2000-08-01 | 2013-12-18 | |
| EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer cilengitide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | Indiana University | 40 | 1999-12-01 | 2014-09-17 |
| PS-341 in Treating Patients With Advanced Cancer bortezomib - Leukemia, Lymphoma | Phase 1 | Completed | Mayo Clinic | 1999-11-01 | 2011-08-03 | |
| Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer filgrastim, cyclosporine, methylprednisolone - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1 | Completed | Northwestern University | 1999-10-01 | 2012-06-01 |
Showing 20 of 28. Sign in to see all of them.
Multiple Myeloma (24) · Monoclonal Gammopathy of Undetermined Significance (19) · Neoplasms, Plasma Cell (17) · Burkitt Lymphoma (15) · Immunoglobulin Light-chain Amyloidosis (15) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Leukemia, Myeloid, Acute (15) · Lymphoma, Follicular (15) · Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma, Mantle-Cell (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Leukemia (14) · Leukemia, Hairy Cell (14) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma, Large-Cell, Immunoblastic (14)
Hemic and Lymphatic Diseases (28) · Neoplasms (28) · Blood Protein Disorders (27) · Hematologic Diseases (27) · Immune System Diseases (27) · Immunoproliferative Disorders (27) · Paraproteinemias (27) · Neoplasms by Histologic Type (25) · Cardiovascular Diseases (24) · Hemorrhagic Disorders (24) · Hemostatic Disorders (24) · Lymphoproliferative Disorders (24) · Vascular Diseases (24) · Bone Marrow Diseases (16)
Lenalidomide (5) · Peripheral Blood Stem Cell Transplantation (4) · Bortezomib (3) · Cyclophosphamide (3) · Filgrastim (3) · Calcium Dobesilate (2) · Carboplatin (2) · Cyclosporine (2) · Dexamethasone (2) · Granulocyte Colony-Stimulating Factor (2) · Melphalan (2) · Methylprednisolone (2) · PVX-410 vaccine (2) · sargramostim (2) · Amifostine (1)
City of Hope Medical Center (2) · Janssen Research & Development, LLC (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Northwestern University (2) · Benovus Bio, Inc. (1) · California Cancer Consortium (1) · Cancer Treatment Centers of America (1) · Indiana University (1) · Jennifer Woyach (1) · Kyowa Kirin Co., Ltd. (1) · LifeTime Pharmaceuticals (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · NYU Langone Health (1)
United States (27) · Australia (1) · Belgium (1) · Israel (1) · Netherlands (1) · Norway (1) · Philippines (1) · Russia (1) · Spain (1) · United Kingdom (1)
Noopur Raje, MD (2) · Richard K. Burt, MD (2) · Ajay Nooka, MD (1) · Alex A. Adjei, MD, PhD (1) · Choon-Kee Lee, MD (1) · Fredik Schjesvold, MD PhD (1) · George Somlo (1) · George Thomas Budd, MD (1) · Howard S. Hochster, MD (1) · Jeffrey S. Weber, MD, PhD (1) · Jennifer A Woyach, MD (1) · John Lust (1) · Leonard B. Saltz, MD (1) · Loan Hoang-Sayag, MD (1)
PMID 26853648, PMID 30128502, PMID 30562587, PMID 32427579, PMID 41100731
P30CA015083 (2), 2009 (1), P30CA016058 (1), P30CA016087 (1), P30CA023074 (1), P30CA072720 (1), U01CA062487 (1), U01CA062491 (1), U01CA062502 (1), U01CA062505 (1), U01CA069912 (1), U01CA099168 (1)